

ABSTRACT

Novel, stable pharmaceutical formulations for the oral administration of high purity torsemide modification II are disclosed. These formulations release high purity torsemide modification II in water at a constant and high purity rate, and the high purity torsemide modification II therein does not
5 rearrange to torsemide modification I over time. Methods for their manufacture are also disclosed.

10071423.020802